Hepatitis B
Home Merck Studies France HiB or H.influenza Multiple sclerosis Adverse Reactions Hep B Alzheimer's Hepatitis B twelve hours old Universal hep B program Guillian Barre Hepatitis B positive mothers Corixa MF-59 Recombinant vaccines Squalene Yeast

Hepatitis B

Text Box:

This disease can cause cirrhosis of the liver as well as liver cancer. However, this virus is sexually transmitted. People at high risk for getting hepatitis B disease (which is transmitted by coming into direct contact with an infected person's body fluids) are IV drug users, prostitutes, prisoners, and sexually promiscuous persons. This vaccine is produced from cultures commonly found in baker’s yeast. The vaccine is treated with formaldehyde and contains 95 percent hepatitis B virus surface antigen, 4 percent yeast protein,  and aluminum hydroxide.  The only babies at risk for this disease are babies born to Hepatitis B positive mothers and it is just that, a risk, not a given. In 1996, fifty-four cases were reported to the Center for Disease Control in the birth-to-1 age group. There were 3.9 million babies born that year so the incidence of hepatitis B is 0.001%. Does that sound like enough cases to warrant a vaccine? 90 to 95% of all hepatitis B cases recover completely after 3 to 4 weeks of nausea, fatigue, headache, arthritis, jaundice and tender liver. Approximately 50% of patients who contract Hepatitis B develop no symptoms after exposure. However, the exposure ensures that they will have life-time immunity. An additional 30% develop only flu-like symptoms, and again, this group will acquire life-time immunity. Of the remaining 20% exposed to Hepatitis B will develop the symptoms of the disease. 95% of this 20% will fully recover, with life-time immunity. Therefore, less than 5% of people who contract Hepatitis B will become chronic carriers of the infection.

Up to 17 percent of all hepatitis B vaccinations are followed by reports of fatigue and weakness, headache, arthritis and fever of more than 100 F.  The vaccine can cause death, according to a 1994 Institute of Medicine report.

The Hepatitis B vaccine is the first one a baby is subjected to at twelve hours old. This is in hopes it will protect them when they are older. Developed in 1987, little is known whether immunity will last until one might fall into a high-risk category. It was originally targeted for promiscuous, needle injecting drug users, but when they wouldn’t come in for the shots the CDC decided to get these kids before they started “using.” Paradoxically, the CDC's own Fact Sheet on the hepatitis B disease does not include newborn babies as a risk group for that disease. So in the CDC’s own words, almost every newborn US baby is now greeted on its entry into the world by a vaccine injection against a sexually transmitted disease for which the baby is not at risk. All this because they couldn't get the junkies, prostitutes, promiscuous heterosexuals and homosexuals they believe to be at risk, to take the vaccine. This is the essence of the hepatitis B universal vaccination program. 

The Physician's Desk Reference cites lethal adverse reactions to the hepatitis B in less than 1 percent. However, if more than 70 million American children receive the vaccine that means more than 700,000 children are likely to die. An ongoing holocaust, to which we hear nothing about. This is just one of twenty different doses of vaccines. Once you assume that a certain number of children are expendable, where do you draw the line?

 The central fact, and the one that helps to explain these insane recommendations, is that the maker of hepatitis B vaccine,  Merck makes one billion dollars a year from this vaccine. A billion dollars a year goes a long way toward influencing public policy.

The group that is pushing this through is called The Hepatitis B coalition. Part of the Immunization Action Coalition, this group was started by a $750,000 grant from the CDC. The World Health Organization, World Bank, Rockefeller Foundation and ongoing funding from Smith-Kline, Merck, Aventis and Johnson & Johnson support it. 

In the single dose hepatitis B vials, the drug companies have replaced the mercury with aluminum, which is another potent neurotoxin that has been associated with Alzheimer's. But who knows what damage it will do to the immature central nervous system of a one-day old infant.

A manufacturer's representative was asked in a 1997 Illinois Board of Health hearing to show evidence that the hepatitis B vaccine is safe for a 1-day old infant. The representative stated:

"We have none. Our studies were done on 5- and 10-year-olds."

--The Congressional Quarterly, August 25, 2000, pg. 647

Merck’s package insert states the following adverse effects have been documented; Rheumatoid Arthritis, Influenza, Vertigo, Myalgia, earache, dysuria, hypotension, Guillain-Barré syndrome, Multiple Sclerosis, myelitis, peripheral neuropathy such as Bell’s Palsy, radiculopathy and visual disturbances. Nothing is known about the long-term effects of this vaccine as no long-term large-scale controlled studies have been done.   Children under the age of fourteen are three times more likely to suffer adverse effects including death following the Hepatitis B vaccine than to catch the disease itself.  For more adverse effects click here

The only recombinant vaccine currently in use in humans is the Hepatitis B Virus (HBV) Recombinant vaccines are those in which genes for desired antigens are inserted into a vector, usually a virus, that has a very low virulence.

The vector expressing the antigen may be used as the vaccine, or the antigen may be purified and injected as a subunit vaccine. Advantages of recombinant vaccines are that the vector can be chosen to be not only safe but also easy to grow and store, reducing production cost. Antigens which do not elicit protective immunity or which elicit damaging responses can be eliminated from the vaccine, and proteins expressed on a virus, even if it is not the usual pathogen, are more likely to have their native conformation. Disadvantages of recombinant vaccines are their cost to develop, since the genes for the desired antigens must be located, cloned, and expressed efficiently in the new vector. The only recombinant vaccine currently in use in humans is the Hepatitis B Virus (HBV) vaccine, which is a recombinant subunit vaccine. Hepatitis B surface antigen is produced from a gene transfected into yeast cells and purified for injection as a subunit vaccine. This is much safer than using attenuated HBV, which could cause lethal hepatitis or liver cancer if it reverted to its virulent phenotype.

 

In 1997, U.S. federal health officials acknowledged that one of their own studies showed that particularly in older children, the vaccine may increase insulin dependent diabetes mellitus, but more studies are needed. France has already discontinued the Hepatitis B vaccine. Here is one study from there.

 

Autoimmun Rev. 2005 Feb;4(2):96-100. Related Articles, Links
Autoimmune hazards of hepatitis B vaccine.
Girard M. 1 bd de la Republique 78000-Versailles, France.

According to Hippocratic tradition, the safety level of a preventive medicine must be very high, as it is aimed at protecting people against diseases that they may not contract. This paper points out that information on the safety of hepatitis B vaccine (HBV) is biased as compared to classical requirements of evidence-based medicine (EBM), as exemplified by a documented selectivity in the presentation or even publication of available clinical or epidemiological data. Then, a review is made of data suggesting that HBV is remarkable by the frequency, the severity and the variety of its complications, some of them probably related to a mechanism of molecular mimicry leading to demyelinating diseases, and the others reproducing the spectrum of non-hepatic manifestations of natural hepatitis B. To be explained, this unusual spectrum of toxicity requires additional investigations based upon complete release of available data.

PMID: 15722255 [PubMed - as supplied by publisher]
 

If you would like to see the package insert on how this vaccine is made click on the healthy liver. 

                                                                                                                        

Here is an excerpt:

The antigen is harvested and purified from fermentation cultures of a recombinant strain of the yeast Saccharomyces cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation process involves growth of Saccharomyces cerevisiae on a complex fermentation medium which consists of an extract of yeast, soy peptone, dextrose, amino acids and mineral salts. The HBsAg protein is released from the yeast cells by cell disruption and purified by a series of physical and chemical methods. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA but may contain not more than 1% yeast protein. The vaccine produced by the Merck method has been shown to be comparable to the plasma-derived vaccine in terms of animal potency (mouse, monkey, and chimpanzee) and protective efficacy (chimpanzee and human).
 

Look at the words in bold and read these studies.

http://www.blackwell-synergy.com/links/doi/10.1111/j.1365-2036.2005.02417.x/abs/

Alimentary Pharmacology & Therapeutics
Volume 21 Issue 7 Page 881 - April 2005
doi:10.1111/j.1365-2036.2005.02417.x


Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet
A. Granito*, D. Zauli*, P. Muratori*, L. Muratori*, A. Grassi*, R. Bortolotti*, N. Petrolini*, L. Veronesi*, P. Gionchetti, F. B. Bianchi* & U. Volta*
Summary

Background: Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic autoantibodies are markers of Crohn's disease and ulcerative colitis respectively.

Aim: To determine the prevalence of anti-S. cerevisiae and perinuclear anti-neutrophil cytoplasmic autoantibodies in a large series of coeliac disease patients before and after gluten free diet, and to correlate anti-S. cerevisiae-positivity with intestinal mucosal damage.

Methods: One hundred and five consecutive coeliac disease patients and 141 controls (22 ulcerative colitis, 24 Crohn's disease, 30 primary sclerosing cholangitis, 15 postenteritis syndrome, 50 blood donors) were tested for anti-S. cerevisiae by enzyme-linked immunosorbent assay and for perinuclear anti-neutrophil cytoplasmic autoantibodies by indirect immunofluorescence.

Results: In coeliac disease anti-S. cerevisiae (immunoglobulin G and/or immunoglobulin A) were slightly less frequent (59%) than in Crohn's disease (75%, P = 0.16) and significantly more frequent than in ulcerative colitis (27%), primary sclerosing cholangitis (30%), postenteritis syndrome (26%) and blood donors (4%) (P = 0.009, P = 0.0002, P = 0.025, P < 0.0001). No correlation was found between anti-S. cerevisiae and degree of mucosal damage. Perinuclear anti-neutrophil cytoplasmic autoantibodies were detected only in one coeliac. After gluten free diet the disappearance of anti-S. cerevisiae-immunoglobulin A (93%) was more frequent than that of immunoglobulin G (17%, P = 0.0001); perinuclear anti-neutrophil cytoplasmic autoantibodies disappeared in the only coeliac positive at diagnosis.

Conclusion: More than half of untreated coeliacs are anti-S. cerevisiae-positive irrespective of the severity of mucosal damage. Differently from immunoglobulin A, anti-S. cerevisiae-immunoglobulin G persisted in more than 80% after gluten free diet. The high prevalence of anti-S. cerevisiae in coeliac disease suggests that they may be the effect of a non-specific immune response in course of chronic small bowel disease.


I wonder if there is some connection?

Here is another study.

http://www.blackwell-synergy.com/links/doi/10.1111/j.1365-2249.2005.02759.x/abs/

Clinical & Experimental Immunology
Volume 140 Issue 2 Page 354  - May 2005
doi:10.1111/j.1365-2249.2005.02759.x
 
 
ORIGINAL ARTICLE
CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients
B. Vander Cruyssen*,1, H. Peeters+,1, I. E. A. Hoffman*, D. Laukens, P. Coucke§, D. Marichal+, C. Cuvelier, E. Remaut, E. M. Veys*, H. Mielants*, M. De Vos+ and F. De Keyser*
 
 Summary

Carriage of CARD15 gene polymorphisms and the serological marker anti-Saccharomyces cerevisiae antibodies (ASCA) are two markers for Crohn's disease (CD). Similar phenotypes have been associated with both markers. In the present study we analysed whether both markers were associated with each other and, if so, whether this association could be explained by a direct link or by an indirect association with those phenotypes. Therefore, we included 156 consecutive Caucasian CD patients and assessed the prevalence of the three common single nucleotide polymorphisms in the CARD15 gene. Serum samples were analysed for IgA and IgG ASCA by ELISA. CD patients with CARD15 polymorphisms were more frequently ASCA positive (OR 2·7 (1.4-5.2); P = 0·002) and had higher titres for ASCA IgA (P = 0·005) and ASCA IgG (P < 0·001) compared to patients carrying the wild type polymorphisms. Multivariate analysis demonstrated that this association was independent from ileal disease, penetrating disease and stricturing disease, the need for resective bowel surgery, familial cases, smoking habits and early age at onset. Homozygotes or compound heterozygotes for CARD15 polymorphisms had significantly more frequent ASCA positivity compared to single heterozygotes (OR 9·1 (1.1-74.2), Pc (corrected P-value) = 0·030). These data indicate that there is a significant association between the carriage of CARD15 polymorphisms and ASCA, independent of the described phenotypes. Moreover, ASCA positivity is more frequent in CD patients carrying 2 CARD15 polymorphisms compared to single heterozygotes

And another......

Gluten for punishment: Better eating puts celiac symptoms on the shelf
By Heather V. Eng
Sunday, August 7, 2005

http://theedge.bostonherald.com/healthNews/view.bg?articleid=96916
Do you know the Muffin Man?

Unless he's bearing gluten-free baked goods, more than 2 million Americans living with celiac disease avoid him like the plague. The autoimmune disease causes inflammation in the small intestine when gluten proteins from wheat, rye, barley and related grains are ingested. Celiac disease once was thought rare, but now is believed to affect 1 in 133 Americans. ``I'm seeing a lot more kids with celiac disease, but it's because of increased awareness of patients and pediatricians,'' said Dr. Gary Russell, a pediatric gastroenterologist at Massachusetts General Hospital.

Increased awareness? Or more kids getting Hep B vaccine at birth? If this isn't enough to help you make a decision not to inject your baby with Hep B vaccine, let me tell you about a company making a new Hep B vaccine for use first in England. Why England is not learning from the first lesson is beyond me.
 
The company is named Corixa and the new vaccine is called Fendrix. Here is the web

 address:http://www.corixa.com/default.asp?pid=release_detail&id=262&year=2005

In case it disappears, I have saved it here Corixa

Corixa announces European approval for Fendrix®,
GlaxoSmithKline Biologicals' hepatitis B vaccine containing Corixa's MPL® adjuvant

02/08/2005

SEATTLE, February 8, 2005
 
Corixa Corporation (Nasdaq: CRXA), a developer of immunotherapeutics, today announced that GlaxoSmithKline Biologicals (GSK Bio) has received European approval for its hepatitis B vaccine, Fendrix®, containing Corixa’s MPL® adjuvant.

One of the  first vaccines made with an extremely dangerous  oil based adjuvant was 'Vaccine A' or Anthrax vaccine. In his book lauded Author  Gary Matsumoto has ruthlessly documented the account of the cover-up of the true cause of Gulf War syndrome. He began his research while an embedded reporter for the New York Times during the first Gulf War.   In his book Gary Matsumoto chronicles the use of this adjuvant from its early beginnings as Freund's complex through all of its incarnations. Other names for the adjuvant have been squalene, Tri-mix, DeTox, MF-59, MF59-100 and now the latest MPL. Experiments started in the 30’s, and by the 50’s scientists knew this adjuvant caused autoimmune diseases. Some of the side effects of the earlier versions are allergic spermatogenesis (stoppage of sperm production), MS, neuritis, blindness, lupus.

  The problem is the adjuvant is an oil closely resembling the body's own lipids. It is designed to stimulant a heightened immune response which it does with a vengeance.  Unfortunately after a period of time the body can become confused and attack it's own very similar oil or lipids.  This process is called autoimmune. Russian researchers have referred to this adjuvant as a 'time bomb.' This book chronicles the experiments done on our service men and the carnage that has resulted. The latest of the experiments is about to begin on Europe's smallest, twelve hour old babies in England. Since this vaccine is given so soon after birth, the resulting problems may not initially be attributed to the vaccine. We will have to watch England's babies closely to see if we lose another generation of kids to autoimmune diseases and sterility. Take a look at what doctors at the University of Florida discovered about the adjuvant here:

 
Biomed Pharmacother. 2004 Jun;58(5):325-37.
 

Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Florida, ARB-R2-156, 1600 SW Archer Road, P.O. Box 100221 Gainesville, FL 32610-0221, USA.

Adjuvant oils such as Bayol F (Incomplete Freund's adjuvant: IFA) and squalene (MF59) have been used in human and veterinary vaccines despite poor understanding of their mechanisms of action. Several reports suggest an association of vaccination and various autoimmune diseases, however, few were confirmed epidemiologically and the risk of vaccination for autoimmune diseases has been considered minimal. Microbial components, not the adjuvant components, are considered to be of primary importance for adverse effects of vaccines. We have reported that a single intraperitoneal injection of the adjuvant oils pristane, IFA or squalene induces lupus-related autoantibodies to nRNP/Sm and -Su in non-autoimmune BALB/c mice. Induction of these autoantibodies appeared to be associated with the hydrocarbon's ability to induce IL-12, IL-6, and TNF-alpha, suggesting a relationship with hydrocarbon's adjuvanticity. Whether this is relevant in human vaccination is a difficult issue due to the complex effects of vaccines and the fact that immunotoxicological effects vary depending on species, route, dose, and duration of administration. Nevertheless, the potential of adjuvant hydrocarbon oils to induce autoimmunity has implications in the use of oil adjuvants in human and veterinary vaccines as well as basic research. Copyright 2004 Elsevier SAS

PMID: 15194169 [PubMed - indexed for MEDLINE

How much money is made on this vaccine? Here is except from this article found here...

http://www.in-pharmatechnologist.com/news/printNewsBis.asp?id=73554

SciGen aims for a share of the multibillion hep B vaccine market

By Susan Gotensparre


22/01/2007- Biopharmaceutical firm SciGen has invested $30m (€23.2m) in a hepatitis B vaccine manufacturing plant in Israel, expecting to capture up to 15 per cent of the global market during a three year period.

SciGen has announced the official opening of its $20m (€15.5m) vaccine manufacturing facility in Israel, supplying three million doses of the company’s third generation hepatitis B vaccine, Sci-B-Vac. The company is boosting their vaccine manufacturing to be able to ensure supply to their European and Asian commercial partners. In addition, a further $10m (€7.7m) has been invested to expand the Israeli facilities.

The world market for hepatitis B is $1.2bn (€0.93bn) - Europe and the Asia Pacific region represent 40 per cent - but is expected to increase due to rising awareness of hepatitis B and increased public health expenditure, according to SciGen. The firm has high expectations of explosive annual sales figures from the third quarter of 2007, followed by an anticipated triple digit growth in 2008.

Take a look at this:

 VACCINES are listed as a cause more than once:

http://www.emedicine.com/ped/topic2555.htm

Background: Gianotti-Crosti syndrome (GCS) is a distinct infectious exanthem with associated lymphadenopathy and acute anicteric hepatitis. Gianotti and Crosti initially described GCS as associated with a hepatitis B virus exanthem, which they termed papular acrodermatitis of childhood. A similar constellation of
characteristics was later found to be associated with several infectious agents and immunizations that were called papulovesicular acrolocated syndromes. Subsequent retrospective studies have shown that these 2 entities are indistinguishable from one another, and they are now consolidated under the unifying title of GCS.

Pathophysiology: The most likely explanation for the exanthem is a local type IV hypersensitivity reaction to the offending viral or bacterial antigen within the dermis. This is based on the immunohistochemical characterization of the cutaneous inflammatory infiltrate. Findings on direct immunofluorescence examination of the skin are always negative. Electron microscopy has never revealed virus particles that suggested a reactive process other than an autoimmune phenomenon or direct infection of the skin. Inciting factors include various viral and bacterial infections, as well as recent immunizations. The rarity of GCS in adults suggests lifelong immunity to a common viral triggering agent. GCS is more common among children with atopic dermatitis, suggesting an immune mechanism. However, more information is needed in order to define the precise mechanism involved.

Frequency:

* In the US: Because of the benign self-limited nature of GCS, most cases are not reported, and the overall incidence is unknown. Frequency probably parallels the incidence of a precipitating infection in a specific geographic region.

* Internationally: The underlying infection correlates with the endemic pathogens of a specific geographic region. For example, in Japan and Mediterranean countries, GCS is more commonly associated with hepatitis B virus infection. With the advent of more universal hepatitis B immunization, Epstein-Barr virus is now the most common etiologic factor worldwide.

Mortality/Morbidity:

* The mere presence of a rash elicits some degree of social morbidity, depending on the age of the affected child.

* Although typically nonpruritic, some reports document pruritus in the later stages of the rash.

* The only significant morbidity involves the underlying infectious process, particularly the hepatitis B virus.

Race: No racial predilection has been noted; however, the underlying infection correlates with the endemic pathogens of a specific geographic region.

Sex: In the pediatric population, GCS affects males and females with equal frequency. However, affected adults have been exclusively female.

Age: GCS primarily occurs in children aged 3 months to 15 years, with a peak in children aged 1-6 years. More than 90% of patients are younger than 4 years.

 

 

Page 12